Innovent Biologics, Inc. ('Innovent') (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, ...

What The Latest NCCN and ASCO Guidelines Mean for HR-Positive Breast Cancer Treatment Optimizing Metastatic HR-Positive Breast Cancer Treatment: The Role of Molecular Testing William J. Gradishar, MD, ...

Vepdegestrant becomes the first FDA-approved heterobifunctional protein degrader (PROTAC) in breast cancer, targeting ER signaling in endocrine-resistant ESR1-mutant disease. Biomarker gating is ...

David Portman - Sermonix Pharmaceuticals, Inc. Good afternoon, and thank you for joining LeonaBio's key opinion leader call. [Operator Instructions] A replay of today's event will be available on the ...

Uterine mesonephric-like adenocarcinoma (MLA) is a rare and biologically aggressive subtype of endometrial carcinoma, estrogen receptor (ER) and progesterone receptor (PR) are typically absent or ...

Randomized IDE study met all primary and secondary safety and efficacy endpoints and demonstrated superior debris capture and significantly higher technical success versus the leading embolic ...

ICESECRET enrolled 114 patients with 138 SRM lesions ≤5 cm and used CT-guided ProSense ablation with standardized follow-up at 6 weeks, 6 months, 1 year, then annually through year 5. Recurrence-free ...

A preoperative trial shows that activating the progesterone receptor with low-dose megestrol can deepen estrogen blockade and curb tumor proliferation, without added toxicity, pointing to a simpler ...

– Giredestrant is the only oral SERD to show superior invasive disease-free survival in the adjuvant setting, marking the first significant endocrine therapy advance in over 20 years – – ...

– ER-positive breast cancer accounts for approximately 70% of breast cancer cases, and up to a third experience recurrence on or after adjuvant endocrine therapy treatment – – Data will be featured in ...

Patients with estrogen-receptor-positive HER-2-negative advanced breast cancer showed significantly improved progression-free survival when treated with an oral combination regimen that includes ...